GlassScriptPhysician profile
Gilda Mark
NPI 1700124617
$7,747.50
in general payments reported to CMS, 2019-2025
12 companies · $2,673 in 2025
The $2,673 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $697 · 2023: $2,097 · 2024: $2,030 · 2025: $2,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,622 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,622.12 |
| Education | $177.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,569.39 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,692.65 | 2022-2025 | Caplyta |
| Alkermes, INC. | $1,278.83 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $976.29 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $718.98 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $296.35 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $81.71 | 2023-2025 | Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $37.78 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $27.98 | 2024 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $24.60 | 2022 | |
| Abbvie INC. | $24.51 | 2025 | |
| Janssen Scientific Affairs, LLC | $18.43 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilda Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.